American Heart Association Scientific Sessions

Expert Opinion on Investigational Drugs

Volumn 13, Issue 4, 2004, Pages 435-445

  Winkelmann, Bernhard R ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ACE inhibitor; Acute myocardial infarction; Angiotensin receptor blocker; Atrial fibrillation; Coronary artery disease; Heart failure; Microalbuminuria

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARIPORIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENIPORIDE; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; PRAVASTATIN; RAMIPRIL; TELMISARTAN; THROMBIN INHIBITOR; TOLVAPTAN; VALSARTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR; WARFARIN; XIMELAGATRAN;

ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; ATHEROSCLEROSIS; BLEEDING; BRADYCARDIA; CARDIOLOGY; CEREBROVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONSENSUS DEVELOPMENT; COUGHING; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ENZYME INHIBITION; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LIVER DYSFUNCTION; MEDICAL SOCIETY; MICROALBUMINURIA; MYOPATHY; NEUROLOGIC DISEASE; NONHUMAN; QT PROLONGATION; RECEPTOR BLOCKING; SIDE EFFECT; STROKE; SURVIVAL; TASTE DISORDER; TREATMENT OUTCOME; UNITED STATES;

AMERICAN HEART ASSOCIATION; ARRHYTHMIA; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; GUANIDINES; HUMANS; SULFONES; UNITED STATES;

EID: 1942504289     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.4.435     Document Type: Conference Paper

References (11)

1. KARMAZYN M: Pharmacology and clinical assessment of cariporide for the treatment coronary artery diseases. Exp. Opin. Invest. Drugs (2000) 9:1099-1108.
2. THÉROUX P, CHAITMAN BR, DANCHIN N et al.: For the Guard During Ischemia Against Necrosis (GUARDIAN) investigators. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations - main results of the GUARDIAN trial. Circulation (2000) 102:3032-3038.
3. + exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction - results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) Trial. J. Am. Coll. Cardiol. (2001) 38:1644-1650.
4. PFEFFER MA, McMURRAY JJV, VELAZQUEZ EJ et al.: For the valsartan in acute myocardial infarction trial investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. (2003) 349:1893-1906.
5. DICKSTEIN K, KJEKSHUS J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet (2002) 360:752-760.
6. COHN JN, TOGNONI G: For the valsartan heart failure trial investigators. A randomized trial of the angiotensin-receptor inhibitor valsartan in chronic heart failure. N. Engl. J. Med. (2001) 345:1667-1675.
7. McMURRAY JJV, OSTERGREN J, SWEDBERG K et al.: For the CHARM investigators and committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362:759-756.
8. UNGER T: The ongoing telmisartan alone and in combination with ramipril global endpoint trial program [ONTARGET]. Am. J. Cardiol. (2003) 91:28G-34G.
9. NISSEN SE, TUZCU EM, SCHOENHAGEN P et al; For the REVERSAL Investigators. Effects of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA (2004) 291:1071-1080.
10. CANNON CP, BRAUNWALD E, McCABE CH et al.: for the Pravastatin and Atorvastatin Evaluation and Infection Therapy -Thrombolysis in Myocardial Infarction 22 Investigators. Comparision of intensive and moderate lipid-lowering with statins after acute coronary syndromes. N. Engl. J. Med. (2004) 350(15) (Epub ahead of print).
11. HALPERIN JL, EXECUTIVE STEERING COMMITTEE, SPORTIF III AND V STUDY INVESTIGATORS: Ximelagatran compared with warfarin for prevention of thromboembolism, in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline characteristics (SPORTIF III and V). Am. Heart J. (2003) 146:431-438.